Immunovant (IMVT) Long-Term Debt Repayments (2019 - 2020)

Immunovant (IMVT) reported Long-Term Debt Repayments of $134000.0 for Q4 2020, down 33.66% quarter-over-quarter from $202000.0 in Q3 2020.

Immunovant (IMVT) Long-Term Debt Repayments (2019 - 2020) Analysis & Trends

Immunovant has reported Long-Term Debt Repayments for 2 years, with the latest figure at $134000.0 in Q4 2020.

For the quarter ending Q4 2020, Long-Term Debt Repayments changed N/A year-over-year to $134000.0; the trailing twelve-month figure through Sep 2021 stood at $134000.0 (down 95.62% YoY), and the FY2021 full-year result was $3.2 million, up 27.6% from the prior year.
Long-Term Debt Repayments for Q4 2020 stood at $134000.0, down from $202000.0 in the prior quarter.
The five-year high for Long-Term Debt Repayments was $2.9 million in Q2 2020, with the low at $134000.0 in Q4 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	LT Debt Repayment (Qtr)
1	Alterity Therapeutics	762,369.55 Bn	762,369.51 Bn	-	-
2	Belite Bio	55,096.00 Bn	55,096.00 Bn	-	-
3	Quantum Biopharma	17,755.80 Bn	17,755.79 Bn	-	-21,671.00
4	Legend Biotech	3,486.00 Bn	3,485.71 Bn	242.10 Mn	-
5	Akari Therapeutics	1,737.42 Bn	1,737.41 Bn	-	-
6	Evaxion A	1,551.28 Bn	1,551.26 Bn	-	-
7	Psyence Biomedical	227.32 Bn	227.31 Bn	-	-
8	Vertex Pharmaceuticals	110.84 Bn	103.59 Bn	2.59 Bn	-
9	Abivax	91.71 Bn	91.71 Bn	-	-
10	Immunovant	5.71 Bn	5.71 Bn	-	-

Download Data